2018 American Transplant Congress
Clinically Relevant Variation of Donor-Derived Cell-Free DNA during Longitudinal Surveillance of Renal Allografts
Purpose: Donor-derived cell-free DNA (dd-cfDNA) levels >1% are associated with active rejection in renal transplant recipients. This report defines the clinically relevant variation of dd-cfDNA…2018 American Transplant Congress
Living-Donor Preemptive Kidney Transplant Timing Calculator: An Online Decision Support Tool
Purpose: Optimal glomerular filtration rate (GFR) and timing for living preemptive kidney transplantation (PKT) is not well studied.Method: We developed an online engine to calculate…2018 American Transplant Congress
Everolimus with Reduced-Dose Calcineurin Inhibitor versus Mycophenolate with Standard-Dose Calcineurin Inhibitor in De Novo Kidney Transplant Recipients: Renal Function Results from the TRANSFORM Study
1TRANSFORM Study Group, Barcelona, Spain; 2Novartis Pharma AG, Basel, Switzerland.
Purpose: TRANSFORM (NCT01950819) is the largest study conducted in de novo kidney transplant recipients (KTxRs) to evaluate the benefit of everolimus with reduced-dose calcineurin inhibitor…2018 American Transplant Congress
Epitope/Eplet Mismatch in Pediatric Renal Transplantation and Development of Donor Specific Antibody
Background: De-novo donor specific antibody (DSA) is one of the strongest independent predictors of graft loss with HLA mismatching being a major risk factor for…2018 American Transplant Congress
Determining the Relative Immunogenicity of HLA Mismatches with Calcineurin Inhibitor Immunosuppression: An Analysis of the BENEFIT and BENEFIT-EXT Renal Transplant Cohort
We studied the relative immunogenicity of HLA-A, -B, -C, -DR and -DQ MM (serological) in a cohort of 291 kidney transplant patients from the BENEFIT…2018 American Transplant Congress
Ciprofloxacin for BK Viremia Prophylaxis in Kidney Transplant Recipients: Results of a Prospective, Randomized Controlled Trial
Houston Methodist Hospital, Houston, TX.
Fluoroquinolone (FQ) antibiotics have in vitro activity against BK virus, with several reports indicating they may reduce the risk of BK infection in kidney transplant…2018 American Transplant Congress
Significant Anti-CMV/BKV Effect of a Modern Everolimus-Based Regimen Comparted to a Standard Tacrolimus-MPA Regimen in De Novo Kidney Transplant Recipients: ATHENA 12 Months Data on Infections
1Athena Study Group, Germany; 2Athena Study Group, France; 3Novartis, Pharma, Germany.
The ATHENA trial was designed to compare everolimus [EVR] in combination with tacrolimus [TAC] or cyclosporine A [CyA] vs. a standard regimen of mycophenolic acid…2018 American Transplant Congress
Effect of Induction Therapy on CD4 Cell Count Recovery Following Renal Transplantation in HIV Positive Recipients – A Single Center Experience
Department of Transplantation, Mayo Clinic College of Medicine, Jacksonville, FL.
The feasibility, complications and outcomes of solid organ transplantation in the HIV positive population are well documented and have had excellent outcomes with a slight…2018 American Transplant Congress
Are Donation after Cardiac Death (DCD) Kidneys Unsuitable for Pediatric Recipients?
Introduction: Despite the fact that the number of pediatric patients listed for kidney transplantation far exceeds the supply of deceased donor kidneys, there is a…2018 American Transplant Congress
Long Term Outcomes of Renal Allografts with De Novo DSA in the Setting of Stable Graft Function versus Acute Rejection
We sought to compare the long-term outcome of renal allograft recipients with de novo DSA (dnDSA) in the setting of stable allograft function versus dnDSA…
- « Previous Page
- 1
- …
- 324
- 325
- 326
- 327
- 328
- …
- 531
- Next Page »